• Joanna Gora-Tybor, Ewa Medras, Malgorzata Calbecka, Agnieszka Kolkowska-Leśniak, Edyta Ponikowska-Szyba, Tadeusz Robak, and Krzysztof Jamroziak.
• a Institute of Hematology and Transfusion Medicine , Warsaw , Poland.
• Leuk. Lymphoma. 2015 Jan 1; 56 (8): 2309-14.

AbstractWe retrospectively analyzed the rates of significant non-hematological adverse events (AEs) in 105 patients with chronic myeloid leukemia (CML) treated with second-generation tyrosine kinase inhibitor (TKIs) dasatinib or nilotinib used as second-line therapy in Polish tertiary care centers. Our analysis revealed that in a "real life setting," nearly half of patients with CML on second-generation TKIs suffer from therapy complications. Grade 2-5 non-hematological AEs were observed in 40% of patients treated with nilotinib and in 42% treated with dasatinib (p=0.83). Severe vascular events including peripheral artery occlusive disease (PAOD) occurred in 11% of patients on nilotinib and 4% on dasatinib (p=0.16). Pleural effusion occurred more often in the dasatinib group (26%) than in the nilotinib group (2%) (p=0.003). Importantly, most AEs occurred late, after more than 1 year of treatment. Since AEs are most often the reason for poor therapy compliance, careful monitoring of tolerability is crucial for an optimal treatment response in CML.

39 keywords...

hide…